


Claims

1. A compound of formula (I):




wherein:

Y is phenyl, substituted with one, two or three substituents;

R¹ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, or halosubstituted C₁₋₆ alkyl;

R² is (CH₂)_mR³;

R³ is an unsubstituted or substituted 5- to 6- membered aromatic heterocyclyl group, or group A:



(A)

R⁴ is selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, or halosubstituted C₁₋₆ alkyl, COCH₃, and SO₂Me;

R⁶ is unsubstituted or substituted (C₁₋₆)alkyl or chloro and R¹⁰ is hydrogen or R¹⁰ is unsubstituted or substituted (C₁₋₆)alkyl or chloro and R⁶ is hydrogen;


Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb can independently be selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo substituted C₁₋₆ alkoxy, hydroxy, cyano, halo, sulfonyl, CONH₂, COOH, SO₂CH₃, NHCOCH₃, NHSO₂CH₃ and CONHCH₃;

m is 1 or 2;

or a pharmaceutically acceptable derivative thereof.


2. A compound as claimed in claim 1 wherein the compound is of formula (Ia):



wherein

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstituted C_{1-6} alkyl;

R^3 is furanyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thienyl, pyrazolyl, tetrazolyl, pyridyl, pyrizinyl, pyrimidinyl, pyrazinyl, triazinyl, or tetrazinyl which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, halosubstituted C_{1-6} alkoxy, halosubstituted C_{1-6} alkyl, hydroxy, cyano, halo, sulfonyl, $CONH_2$ and $COOH$, or R^3 is group A:



R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, or halosubstituted C_{1-6} alkyl, $COCH_3$, and SO_2Me ;

R^6 is unsubstituted or substituted (C_{1-6})alkyl, chloro and R^{10} is hydrogen or R^{10} is unsubstituted or substituted (C_{1-6})alkyl or chloro and R^6 is hydrogen;

R_a can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

R_b can independently be selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, halosubstituted C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, $COOH$, SO_2CH_3 , $NHCOCH_3$, $NHSO_2CH_3$ and $CONHCH_3$;

R^{11} is C_{1-6} alkyl, halosubstituted C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6} alkylsulfonyl, $CONH_2$, $NHCOCH_3$, $COOH$, halosubstituted C_{1-6} alkoxy, C_{1-6} alkynyl, C_{1-6} alkynyl, $SO_2NR^{8a}R^{8b}$;

d is 1, 2, or 3;

m is 1 or 2;

R^{8a} and R^{8b} are independently selected from hydrogen or C_{1-6} alkyl; or a pharmaceutically acceptable derivative thereof.

3. A compound as claimed in claim 1 or 2 wherein R^1 is hydrogen or C_{1-6} alkyl

4. A compound as claimed in any one of claims 1 to 3 wherein R^4 is hydrogen or methyl.

5. A compound as claimed in any preceding claim whereing R^3 is selected from group A, pyridinyl, pyrimidinyl, imidazolyl, oxadiazolyl, triazolyl or pyrazinyl.

5 6. A compound as claimed in any preceeding claim selected from any one of Examples 1 to 79 or a pharmaceutically acceptable derivative thereof.

7. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof

10

8. A pharmaceutical composition as claimed in claim 7 further comprising a pharmaceutical carrier or diluent thereof.

15

9. A method of treating a human or animal subject suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.